Related Experiment Video

Updated: Jun 8, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Targeting Wee1-like protein kinase to treat cancer

Anastasios Stathis1, Amit Oza

  • 1Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Hospital, and University of Toronto, Toronto, Ontario, Canada.

Drug News & Perspectives
|September 24, 2010
PubMed

Insights

New anticancer agents are needed to overcome chemotherapy resistance. Wee1 inhibition, targeting the G2/M checkpoint, shows promise for enhancing antitumor activity when combined with DNA-damaging therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Cycle Regulation

Background:

  • Cancer cells develop resistance to standard chemotherapy, necessitating novel therapeutic strategies.
  • Targeting molecular pathways driving cancer progression offers a promising approach to improve treatment outcomes.
  • Alterations in cell cycle regulation and DNA damage repair are common in cancer cells.

Purpose of the Study:

  • To review the role of Wee1 tyrosine kinase in controlling the G2/M cell cycle checkpoint.
  • To discuss the effects of abrogation of the G2/M checkpoint via Wee1 inhibition.
  • To present preclinical and clinical data on Wee1 inhibitors, including MK-1775.

Main Methods:

  • Review of scientific literature on Wee1 kinase, cell cycle checkpoints, and anticancer drug development.
  • Analysis of preclinical study results involving Wee1 inhibitors.
  • Evaluation of data from the first reported clinical trial of the Wee1 inhibitor MK-1775.

Main Results:

  • Wee1 tyrosine kinase is a key regulator of the G2/M checkpoint, preventing entry into mitosis.
  • Inhibiting Wee1 can abrogate the G2/M checkpoint, potentially increasing sensitivity to DNA-damaging agents.
  • Preclinical studies confirm enhanced antitumor activity of Wee1 inhibitors with DNA-damaging therapies; early clinical data for MK-1775 are presented.

Conclusions:

  • Wee1 inhibition is a viable strategy to enhance the efficacy of DNA-damaging anticancer therapies.
  • Further clinical evaluation of Wee1 inhibitors like MK-1775 is crucial to establish their role in cancer treatment.
  • Targeting the G2/M checkpoint offers a novel approach to overcome chemotherapy resistance.

More Related Videos

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...